Denise Neves Gameiro, Author at Labiotech.eu

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

News and Trends 24 Nov 2016

A Finnish Company opens a New Avenue to Alternative Protein

How do you solve a problem like the viability of small-scale biogas production? Protein feed with a side of bioplastic, according to the Technical Research Centre of Finland. This emission-reducing process could not only yield interesting biobased products, but also solve some self-sufficiency and food security problems for Europe. Biogas is a promising biofuel, as it […]

November 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

antibiotic resistance biosensor freiburg

News and Trends 18 Nov 2016

Microfluidics and Biosensors to tackle Antibiotic Resistance

A little biosensor can analyze if there are antibiotics in your blood in 10 minutes. Developed by researchers from the University of Freiburg, the system could be used to develop a personalized course of antibiotics, but also to test food and water. The objective? Slow down the rise of multi-resistant bacteria. The World Antibiotic Awareness […]

November 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 14 Nov 2016

USB key Diagnostic could help manage HIV Treatment Anywhere

A new method of gene sequencing has brought us an HIV diagnostic on a “USB stick”, which determines the levels of the virus with one drop of blood and in under 30 minutes. Once perfected, the technology could be the tool for HIV management as glucose meters are for diabetes. While pharma and research work […]

November 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 10 Nov 2016

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […]

November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 8 Nov 2016

Swiss SynBio adds CRISPR to its Toolkit for new Specialty Chemicals

Evolva is licensing the CRISPR patents of Emmanuelle Charpentier, in a deal with holding company ERS Genomics. This will grant access to the wonder gene-editing technology for one of the most important players in European SynBio. Headquartered in Switzerland, Evolva develops new ways to obtain ingredients and specialty chemicals with brewing and engineered microorganisms. Its […]

November 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

biorefinery review europe biomass bioeconomy

In Depth 2 Nov 2016

Green Waste is Biotech’s New Black Gold: A Review of Biorefineries

Replacing petroleum-based products with biobased equivalents is the Holy Grail of the bioeconomy. What are biorefineries doing and how can Biotech help? ‘Biorefinery’ is a buzzword for a cool technological space that draws from GreenTech, Industrial Biotech and SynBio. The core concept behind it is relatively simple: these plants mimic the traditional petroleum refinery, but […]

November 2, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 31 Oct 2016

Meet the Jellyfish Medtech seeking to disrupt the Collagen Market

Jellyfish are a source of collagen: this is the idea behind the winner of Boost Cymru, a competition of the Life Sciences Hub Wales. We had a chat with Andrew Mearns-Spragg, CEO of Jellagen, about this promising startup. The jellyfish already has a place in Biotech’s hall of fame as the source of the gene for […]

October 31, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 19 Oct 2016

This Technology Opens new Horizons for Protein Production

Based in Cologne, Germany, Cevec focuses on human cell-based expression system for production of biological therapies. We’ve already covered their breakthroughs for safer gene therapy and the potential of CAP-GT for expression of viral vectors. Besides CAP-GT, CEVEC has also developed a cell line that can produce complex glycosylated proteins. A good example of glycosylated protein is […]

October 19, 2016 - 5 minutesmins - By Denise Neves Gameiro

biobutanediol mater biotech novamont bioeconomy

News and Trends 12 Oct 2016

Italy has new €100M Factory for Biobased Butanediol

With an industry worth €3.5Bn, butanediol is an important chemical intermediate. Novamont has recently opened the first industrial plant to produce bio-butanediol from sugars, using engineered E. coli. Biotechnology is a key driver in replacing fossil fuels with renewable raw materials, so companies and academia are busy creating ways to produce different chemicals from biomass. Examples […]

October 12, 2016 - 2 minutesmins - By Denise Neves Gameiro

obesity microbiome research kings college

News and Trends 5 Oct 2016

New Link found between the Microbiome and “Genetic Obesity”

Researchers at King’s College London have found a new link between gut microbiome diversity (or, more specifically, the lack of it) and a particularly troubling kind of obesity. This finding could also help explain the inheritability of this disease. The explosive growth of the Microbiome field promises a whole new type of therapies, but this […]

October 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

vienna biotech valneva sanochemia aop pharma

News and Trends 12 Sep 2016

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Classical music, the Danube, Schnitzel, and apple strüdel – a typical combination of Vienna. The city has also been at the top of rankings for quality of life, innovation, and popular host for conferences. But what about Biotech? Once one of the most influential cities in Europe, Vienna might now be somewhat under the radar […]

September 12, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 1 Sep 2016

Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”

Cevec could very well be the missing link between adenoviral vectors and approved gene therapies. I had a chat with the CSO of Cevec about what makes its technology great and how it’s ready for the future of gene therapy. Gene therapy is one of the strongest trends in biotechnology right now. The field has […]

September 1, 2016 - 6 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us